论文部分内容阅读
目的观察节奏性化疗对晚期乳腺癌的疗效及不良反应。方法患者随机分为两组,治疗组采用环磷酰胺100mg/d口服第1~15天,甲氨蝶呤5mg/d口服第1~10天,优福定300mg/d口服第1~15天,28天一个周期,对照组采用环磷酰胺600mg/m2ivgtt第1,8天,阿霉素40mg/m2iv第1,5天-FU 300mg/m2ivgtt第1~5天,亦为28天一个周期,均连用2~4个周期后评价疗效。结果38例均可评价疗效及不良反应。完全缓解1例,部分缓解16例,总有效率(CR+PR)17例,占44.7%,中位生存期8.6个月。主要不良反应为骨髓抑制,均为Ⅰ°。结论节奏性化疗治疗晚期乳腺癌疗效确切,不良反应轻微,可在门诊及院外应用。患者耐受性好。
Objective To observe the curative effect and adverse reactions of rhythmic chemotherapy on advanced breast cancer. Methods Patients were randomly divided into two groups. Patients in the treatment group were treated orally with cyclophosphamide 100 mg / d for days 1 to 15, methotrexate 5 mg / d for days 1 to 10, and orally administered 300 mg / d orally for days 1 to 15 , A cycle of 28 days, the control group with cyclophosphamide 600mg / m2ivgtt first and eighth days, doxorubicin 40mg / m2iv first and fifth days -FU 300mg / m2ivgtt 1 to 5 days, also a 28-day cycle, Even with 2 to 4 cycles after the evaluation of efficacy. Results 38 cases can evaluate the efficacy and adverse reactions. Complete remission in 1 case, partial remission in 16 cases, the total effective rate (CR + PR) in 17 cases, accounting for 44.7%, the median survival of 8.6 months. The main adverse reactions were myelosuppression, all Ⅰ °. Conclusions Rhythmic chemotherapy is effective in the treatment of advanced breast cancer with mild adverse reactions. It can be used in outpatient and outpatient settings. Patients are well tolerated.